Cargando…

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

Detalles Bibliográficos
Autores principales:	Spring, Laura M., Han, Hyo, Liu, Minetta C., Hamilton, Erika, Irie, Hanna, Santa-Maria, Cesar A., Reeves, James, Pan, Peng, Shan, Ming, Tang, Yongqiang, Graham, Julie R., Hazard, Sebastien, Ellisen, Leif W., Isakoff, Steven J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499859/ https://www.ncbi.nlm.nih.gov/pubmed/35931884 http://dx.doi.org/10.1038/s43018-022-00430-w

Ejemplares similares

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
por: Maiorano, Mauro Francesco Pio, et al.
Publicado: (2023)

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2023)

Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
por: Coignard, Juliette, et al.
Publicado: (2021)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Niraparib for ovarian cancer
Publicado: (2021)

Author Correction: Physical activity and sleep behaviour in women carrying BRCA1/2 mutations
por: Galasso, Letizia, et al.
Publicado: (2022)

ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
por: Wei, Qiang, et al.
Publicado: (2022)

Author Correction: Her9/Hes4 is required for retinal photoreceptor development, maintenance, and survival
por: Coomer, Cagney E., et al.
Publicado: (2020)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer
por: Vidula, Neelima, et al.
Publicado: (2021)

Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models
por: Sambade, Maria J, et al.
Publicado: (2019)

Author Correction: Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study
por: Kim, Joo Heung, et al.
Publicado: (2023)

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
por: Medford, Arielle J., et al.
Publicado: (2019)

Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models
por: Mansur, Ameer, et al.
Publicado: (2023)

Author Correction: FAN1 interaction with ubiquitylated PCNA alleviates replication stress and preserves genomic integrity independently of BRCA2
por: Porro, Antonio, et al.
Publicado: (2017)

Author Correction: The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma
por: Araki, Yoshihiro, et al.
Publicado: (2021)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Schettini, Francesco, et al.
Publicado: (2023)

Author Correction: BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity
por: Rasmussen, Rikke D., et al.
Publicado: (2018)

Author Directory
Publicado: (2013)

Author Index
Publicado: (2013)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Author Correction: Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
por: Maoz, Myriam, et al.
Publicado: (2020)

Author Correction: PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
por: Yokoyama, Daiju, et al.
Publicado: (2021)

ASO Author Reflections: Assessing the Impact of Neoadjuvant Therapy: A Real View Perspective
por: Kamarajah, Sivesh K., et al.
Publicado: (2020)

ASO Author Reflections: Neoadjuvant Endocrine Therapy: A Pill in Time Saves Nine
por: Williams, Austin D., et al.
Publicado: (2022)

Author Correction: Structural determinants and functional consequences of protein affinity for membrane rafts
por: Lorent, Joseph H., et al.
Publicado: (2018)

Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2022)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

ASO Author Reflections: Preoperative Prediction of Postmastectomy Radiation Therapy After Neoadjuvant Systemic Therapy
por: Samiei, Sanaz, et al.
Publicado: (2019)

ASO Author Reflections: Disparities in Outcome and Surgical Management Following Neoadjuvant Chemotherapy for Breast Cancer
por: Relation, Theresa, et al.
Publicado: (2021)

ASO Author Reflections: Right Sizing Axillary Surgery in Patients treated with Neoadjuvant Endocrine Therapy
por: Hieken, Tina J., et al.
Publicado: (2021)

Author Correction: Synthesis and comparative evaluation of (177)Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes
por: Sharma, Amit Kumar, et al.
Publicado: (2022)

Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity
por: Walton, Josephine B., et al.
Publicado: (2018)

Author Correction: Comparative analysis of HER2 copy number between plasma and tissue samples in gastric cancer using droplet digital PCR
por: Kim, Boram, et al.
Publicado: (2020)

Author Correction: Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates
por: Joh, Daniel Y., et al.
Publicado: (2021)

ASO Author Reflections: The Pursuit of Eliminating Surgery after Neoadjuvant Systemic Therapy in Breast Cancer Patients
por: van Loevezijn, Ariane A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_79ff4remoaog0n9ctmcb0f9ijb